Elanco Animal Health (NYSE:ELAN) Announces Earnings Results

Elanco Animal Health (NYSE:ELAN) posted its quarterly earnings data on Thursday. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.01, Briefing.com reports. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.04 billion. Elanco Animal Health had a negative net margin of 27.94% and a positive return on equity of 7.29%. The business’s revenue was down 3.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.18 EPS.

Elanco Animal Health Price Performance

Elanco Animal Health stock traded down $0.43 during mid-day trading on Friday, hitting $14.07. 6,249,667 shares of the company were exchanged, compared to its average volume of 4,791,907. The company has a market capitalization of $6.96 billion, a PE ratio of -5.55, a price-to-earnings-growth ratio of 1.31 and a beta of 1.41. The business has a fifty day moving average of $13.95 and a 200 day moving average of $14.71. Elanco Animal Health has a 1-year low of $10.19 and a 1-year high of $18.80. The company has a quick ratio of 1.75, a current ratio of 2.93 and a debt-to-equity ratio of 0.92.

Insider Activity

In other news, CEO Jeffrey N. Simmons bought 100,000 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was acquired at an average price of $13.01 per share, for a total transaction of $1,301,000.00. Following the transaction, the chief executive officer now directly owns 145,000 shares of the company’s stock, valued at $1,886,450. This trade represents a 200.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, Director Michael J. Harrington acquired 3,500 shares of the firm’s stock in a transaction on Thursday, August 22nd. The shares were purchased at an average price of $14.85 per share, with a total value of $51,975.00. Following the acquisition, the director now directly owns 81,094 shares in the company, valued at $1,204,245.90. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CEO Jeffrey N. Simmons bought 100,000 shares of the company’s stock in a transaction on Monday, August 12th. The stock was bought at an average cost of $13.01 per share, with a total value of $1,301,000.00. Following the completion of the purchase, the chief executive officer now owns 145,000 shares of the company’s stock, valued at approximately $1,886,450. The trade was a 200.00 % increase in their position. The disclosure for this purchase can be found here. 0.57% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on ELAN shares. Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $17.00 to $15.00 in a research note on Thursday, September 19th. Stifel Nicolaus restated a “buy” rating and set a $20.00 price objective on shares of Elanco Animal Health in a research report on Thursday, September 19th. Finally, Barclays raised their target price on Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $17.14.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.